As deadline approaches, Senate introduces voucher program renewal bill

With three months left until Congress’ deadline to reauthorize the rare pediatric disease Priority Review voucher program, two senators introduced legislation late last week to make the program permanent.

FDA awards a voucher upon the approval of a drug to treat a rare pediatric disease, which then can be sold or used to gain a six-month review of a future drug, rather than a standard 10-month review. If the voucher program is not renewed by Sept. 30, it will end in September 2022. ...